Global Facial Injectable Market Report 2024

The facial injectable market size has grown rapidly in recent years. It will grow from $12.45 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The increase during the historic period can be attributed to factors such as the growing aging population, increased consumer awareness, changes in beauty standards, regulatory approvals, and advancements in injection techniques.

The facial injectable market size is expected to see rapid growth in the next few years. It will grow to $20.5 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The rise in the forecast period can be attributed to factors such as the increasing demand for non-surgical procedures, broader applications, personalization and customization options, growth in emerging markets, healthcare trends, and shifts in lifestyle preferences. Major trends expected in this period include sustained growth in the demand for non-surgical procedures, the expansion of personalized treatment options, a greater emphasis on combination therapies for improved outcomes, the advancement of minimally invasive techniques and devices, and a preference for natural-looking and subtle results.

The rising interest in cosmetic procedures is expected to drive the growth of the facial injectable market in the coming years. Cosmetic procedures encompass medical treatments aimed at enhancing appearance with minimal disruption to the body's natural structure, often less invasive than traditional surgeries and typically performed on an outpatient basis. This demand is increasing due to societal focus on appearance, safer and more accessible procedures enabled by medical advancements, and a growing desire for self-improvement and confidence boost. Facial injectables are used in cosmetic procedures to temporarily reduce wrinkles, add volume to specific areas, and improve facial contours through precise injection of substances such as botulinum toxin or dermal fillers. For example, in March 2023, a report from the British Association of Aesthetic Plastic Surgeons noted a 102% increase in cosmetic procedures in the UK in 2022, reaching around 31,057 procedures, compared to 2021. Thus, the rising demand for cosmetic procedures is fueling the growth of the facial injectable market.

Leading companies in the facial injectable market are innovating with products such as long-lasting hyaluronic acid (HA) fillers to meet the demand for minimally invasive aesthetic procedures offering natural-looking and enduring results. HA fillers restore volume, smooth wrinkles, and enhance facial contours by replenishing natural skin substances. For instance, in January 2023, Allergan plc introduced JUVEDERM VOLUX XC, an HA filler specifically designed to enhance jawline definition for individuals aged 21 and above with moderate to severe contour loss. Providing effects lasting up to twelve months, JUVEDERM VOLUX XC delivers natural-looking results with minimal downtime, appealing to patients seeking non-surgical options. Supported by research and high patient satisfaction, this filler enables customized treatment plans by cosmetic specialists.

In October 2022, Prollenium Medical Technologies acquired SoftFil for an undisclosed amount, expanding its product range and enhancing its position in the aesthetic medicine industry. This acquisition strengthens innovation and offers comprehensive solutions to practitioners for optimal patient outcomes. SoftFil, a France-based company, produces cosmetic products, aesthetic microcannulas, and facial injectable solutions, complementing Prollenium's portfolio.

Major companies operating in the facial injectable market are AbbVie Inc., Sanofi S.A., Ipsen Pharma, Galderma S.A., Merz Pharma GmbH & Co. KGaA, Sinclair Pharma Plc, Revance Therapeutics Inc., Suneva Medical Inc., Prollenium Medical Technologies, SciVision Biotech Inc., Anteis S.A., Anika Therapeutics Inc., Q-Med AB, Bloomage BioTechnology, Medytox Inc., Teoxane Laboratories, Alphaeon Corporation, BIOPLUS CO. LTD., BioPolymer GmbH & Co. KG, Bioxis Pharmaceuticals, Everest Pharmaceuticals.

North America was the largest region in the facial injectable market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facial injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the facial injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Facial injectables are cosmetic procedures that involve injecting substances into facial tissues to enhance features, diminish wrinkles, restore volume, or enhance overall appearance without surgery. These treatments are commonly used to address aging signs or achieve specific aesthetic goals, offering results that are temporary or semi-permanent.

The primary types of facial injectables include botulinum toxin, collagen, hyaluronic acid, calcium hydroxyapatite, polylactic acid, polymethyl-methacrylate microspheres (PMMA), fat injection, and others. Botulinum toxin is a neurotoxic protein used in cosmetic procedures to temporarily relax muscle activity, primarily for reducing facial wrinkles and lines. These injectables serve various purposes such as wrinkle reduction, facelifts, acne scar treatment, lipoatrophy treatment, lip enhancement, and more. They are used by different end-users including hospitals, ambulatory surgery centers, dermatology and cosmetic clinics, among others.

The facial injectable market research report is one of a series of new reports that provides facial injectable market statistics, including facial injectable industry global market size, regional shares, competitors with a facial injectable market share, detailed facial injectable market segments, market trends and opportunities, and any further data you may need to thrive in the facial injectable industry. This facial injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The facial injectable market consists of sales of platelet-rich plasma (PRP) injections, collagen stimulators, lip injections, and thread lifts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.